Literature DB >> 25901857

Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications.

Giuseppe Di Caro1, Giovanni Francesco Castino, Francesca Bergomas, Nina Cortese, Maurizio Chiriva-Internati, Fabio Grizzi, Alberto Mantovani, Federica Marchesi.   

Abstract

Recruitment of immune and inflammatory cells in the microenvironment of solid tumors is highly heterogeneous and follows patterns, varying according to the organ of origin and stage of disease, with critical roles in the process of cancer onset and progression. While adaptive cells are endowed with anti-tumor activities, inflammatory components of the immune infiltrate orchestrate an immunosuppressive microenvironment that reveals ambivalent functions of the immune contexture in the tumor milieu. The balance between opposing pro-tumoral and anti-tumoral immune pathways, which occur concomitantly in the tumor microenvironment, and the regulatory networks of these phenomena have been the target of several immunotherapeutic strategies. While the scarcity of adaptive immune effectors in tumors correlates with dismal prognosis, the pathways of activation of tumor-specific lymphocytes are yet to be fully elucidated. Recently, the occurrence of tertiary lymphoid tissue was revealed to be critical in mediating the dynamics of T cell recruitment and local activation of immune cells in the tumor microenvironment. Thus, tertiary lymphoid tissue assessment and targeting emerge as a promising approach for the design of novel prognostic immune signatures and immunotherapeutic strategies. The immunological behavior of tertiary lymphoid tissue, its occurrence in the tumor immune microenvironment and its clinical relevance are discussed here.

Entities:  

Keywords:  Biomarker; Immune infiltration; Prognosis; Tertiary Lymphoid Tissue

Mesh:

Year:  2015        PMID: 25901857     DOI: 10.3109/08830185.2015.1018416

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  16 in total

Review 1.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

Review 2.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

3.  Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma.

Authors:  Giovanni Francesco Castino; Nina Cortese; Giovanni Capretti; Simone Serio; Giuseppe Di Caro; Rossana Mineri; Elena Magrini; Fabio Grizzi; Paola Cappello; Francesco Novelli; Paola Spaggiari; Massimo Roncalli; Cristina Ridolfi; Francesca Gavazzi; Alessandro Zerbi; Paola Allavena; Federica Marchesi
Journal:  Oncoimmunology       Date:  2015-09-11       Impact factor: 8.110

4.  Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation.

Authors:  Eun Kyung Kim; Sun Och Yoon; Woon Yong Jung; Hyunjoo Lee; Youngran Kang; You-Jin Jang; Soon Won Hong; Seung Ho Choi; Woo Ick Yang
Journal:  Gastric Cancer       Date:  2016-06-18       Impact factor: 7.370

5.  Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Authors:  Marcella Tazzari; Silvia Brich; Alessandra Tuccitto; Fabio Bozzi; Valeria Beretta; Rosalin D Spagnuolo; Tiziana Negri; Silvia Stacchiotti; Marcello Deraco; Dario Baratti; Chiara Camisaschi; Antonello Villa; Barbara Vergani; Licia Rivoltini; Silvana Pilotti; Chiara Castelli
Journal:  J Immunol Res       Date:  2018-10-29       Impact factor: 4.818

Review 6.  Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy.

Authors:  Liangbin Lin; Xiang Hu; Huiyuan Zhang; Hongbo Hu
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

7.  Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.

Authors:  Pascal Jézéquel; Olivier Kerdraon; Hubert Hondermarck; Catherine Guérin-Charbonnel; Hamza Lasla; Wilfried Gouraud; Jean-Luc Canon; Andrea Gombos; Florence Dalenc; Suzette Delaloge; Jérôme Lemonnier; Delphine Loussouarn; Véronique Verrièle; Mario Campone
Journal:  Breast Cancer Res       Date:  2019-05-17       Impact factor: 6.466

8.  NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal.

Authors:  Sun Och Yoon; Eun Kyung Kim; Mira Lee; Woon Yong Jung; Hyunjoo Lee; Youngran Kang; You-Jin Jang; Soon Won Hong; Seung Ho Choi; Woo Ick Yang
Journal:  Oncotarget       Date:  2016-01-19

9.  A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail.

Authors:  Xiaoting Pan; Heyun Tao; Mengjun Nie; Yuanjie Liu; Pan Huang; Shenlin Liu; Wei Sun; Jian Wu; Ting Ma; Anwei Dai; Jianwei Lu; Baorui Liu; Xi Zou; Qingmin Sun
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

10.  NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma.

Authors:  Eun Kyung Kim; Yoon Ah Cho; Mi-Kyoung Seo; Hyunmi Ryu; Byoung Chul Cho; Yoon Woo Koh; Sun Och Yoon
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.